WallStSmart
PASG

Passage Bio Inc

NASDAQ: PASG · HEALTHCARE · BIOTECHNOLOGY

$4.40
+0.50% today

Updated 2026-06-04

Market cap
$17.87M
P/E ratio
P/S ratio
EPS (TTM)
$-11.84
Dividend yield
52W range
$4 – $20
Volume
0.1M

WallStSmart proprietary scores

28
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C
4.5
Quality
C
3.0
Profitability
D
5.0
Valuation
C+
1/9
Piotroski F-Score
Weak
-17.5
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target
$11.40
+159.09%
12-Month target
Intrinsic (DCF)
Margin of safety
0 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths
+ Debt/equity 0.49x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -17.52 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-12.99M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$0.00$0.00
Net income$-136.13M$-102.06M$-64.77M$-45.52M$-7.56M
EPS$-11.84
Free cash flow$-123.48M$-78.41M$-47.99M$-31.51M$-12.99M
Profit margin

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
PASG$17.87M284.33.05.04.5Avoid
LLY$948.95B7810.010.05.06.0Strong Buy
JNJ$536.54B594.79.03.36.0-71.41%Buy
ABBV$380.57B634.08.04.05.0-55.64%Buy
UNH$343.21B545.35.54.75.5-26.61%Buy
MRK$285.64B503.38.02.75.0-49.34%Hold

Smart narrative

Passage Bio Inc trades at $4.40. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -17.52, it sits in the distress.

Frequently asked questions

What is Passage Bio Inc's stock price?

Passage Bio Inc (PASG) trades at $4.40.

Is Passage Bio Inc overvalued?

Passage Bio Inc carries a Smart Value Score of 28/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Passage Bio Inc (PASG)?

The 12-month analyst consensus target is $11.40, about 159.1% above the current $4.40. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Passage Bio Inc's Altman Z-Score is -17.52, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio
ROE-320.59%
Beta1.38
50D MA$6.55
200D MA$8.48
Shares out0.00B
Float0.00B
Short ratio
Avg volume0.1M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years